1.

RECIST 1.1, mRECIST, RANO-HGG, RANO-BM和iRANO标准之间疗效评价标准的对比

Summary of differences between RECIST 1.1, mRECIST, RANO-HGG, RANO-BM and iRANO assessment criteria

	RECIST 1.1[16]	mRECIST[20]	RANO-HGG[18]	RANO-BM[19]	iRANO[25]
*Specifically, iRANO recommends confirmation of disease progression on follow-up imaging 3 months after initial radiographic progression if there is no new or substantially worsened neurological deficits that are not due to comorbid events or concurrent medication, and it is 6 months or less from starting immunotherapy. If follow-up imaging confirms disease progression, the date of actual progression should be back-dated to the date of initial radiographic progression. The appearance of new lesions 6 months or less from the initiation of immunotherapy alone does not define progressive disease[20, 25]. RECIST: Response Evaluation Criteria in Solid Tumors; mRECIST: modified RECIST; RANO-HGG: response assessment in neuro-oncology for high grade gliomas; RANO-BM: RANO for brain metastases; iRANO: immunotherapy RANO; CR: complete response; PR: partial response; PD: preogressive disease; SD: stable disease.
Measureable lesions	≥10 mm in one diameter	≥5 mm in one diameter	≥10 mm in two diameters	≥10 mm in one diameter	≥10 mm in one diameter (in the case of brain metastases)
Target lesions	2	5	5	5	5
Steroids	Not included	Included	Included	Included	Included
CR	Complete disappearance of all lesions for ≥4 weeks	Complete disappearance of all lesions for ≥4 weeks	Complete disappearance of all lesions for ≥4 weeks; no steroid use; clinically stable/improved	Complete disappearance of all lesions for ≥4 weeks; no steroid use; clinically stable/improved	Complete disappearance of all lesions for ≥4 weeks; no new lesions; no steroids; clinically stable/ improved
PR	≥30% decrease in sum of longest diameters, compared to baseline for ≥4 weeks	≥30% decrease in sum of longest diameters compared to baseline for ≥4 weeks	≥50% decrease in sum of bidimensional products compared to baseline for ≥4 weeks; stable/less steroids; clinically stable/improved	≥30% decrease in sum of longest diameterscompared to baseline for ≥4 weeks; stable/less steroids; clinically stable/improved	≥30% decrease in sum of longest diameters of targetlesions for ≥4 weeks; no new lesions; stable or decreasedsteroid dose; clinically stable/improved
PD*	≥20% increase in sum of longest diameterscompared to nadir, with minimum absoluteincrease of 5 mmnew lesions	≥20% increase in sum of longest diameterscompared to nadirnew lesions	≥25% increase in sum of bidimensional productscompared to nadir; significant T2 signalincrease; new lesions; clinical status worse	≥20% increase in sum of longest diameterscompared to nadir, with minimum absoluteincrease of 5 mm in onelesion; significant T2 signalincrease; clinical status worse	≥20% increase in the sum of longest diameters of targetlesions; or unequivocal progression of enhancingnon-target lesions; or new lesions; or substantial clinicaldecline
SD	Does not meet criteria for CR, PR, or PD	Does not meet criteria for CR, PR, or PD	Does not meet criteria for CR, PR, or PD	Does not meet criteria for CR, PR, or PD	Does not meet criteria for CR, PR, or PD